Download our NEW Mobile App!

Manténgase sano!

Resultados de su búsqueda "Diet Drugs".

Resultados de noticias de salud - 5

09 Nov
Wegovy, Ozempic Probably Won't Harm Vision in People With Diabetes, Study Finds

Wegovy, Ozempic Probably Won't Harm Vision in People With Diabetes, Study Finds

There's good news for people with diabetes who are turning to drugs like Ozempic and Wegovy to treat their disease and lose weight: The drugs probably will not harm their vision.

Semaglutide (the generic name for both medicines) can trigger rapid drops in blood sugar. Pr...

08 Nov
FDA Approves New Diet Drug Zepbound, a Version of the Diabetes Med Mounjaro

FDA Approves New Diet Drug Zepbound, a Version of the Diabetes Med Mounjaro

A second injectable diabetes drug has been approved for weight loss in overweight and obese adults, the U.S. Food and Drug Administration announced Wednesday.

The weight-loss drug Zepbound contains the same active ingredient, tirzepatide, as the diabetes drug Mounjaro. B...

27 Sep
FDA Adds Warning to Ozempic Label About Risk for Blocked Intestines

FDA Adds Warning to Ozempic Label About Risk for Blocked Intestines

Ozempic, a type 2 diabetes drug that has increasingly been used to help with weight loss, will now be labeled as having the potential to block intestines.

The U.S. Food and Drug Administration recently made the

31 May
FDA Issues Warning About Compounded Versions of Wegovy, Ozempic

FDA Issues Warning About Compounded Versions of Wegovy, Ozempic

Patients taking semaglutide for type 2 diabetes or weight loss should be careful about where they're getting the medication, the U.S. Food and Drug Administration

04 May
Pills, Exercise, Dieting: What Works Best to Lose Weight?

Pills, Exercise, Dieting: What Works Best to Lose Weight?

Hundreds of thousands of people are jumping on the Ozempic bandwagon and taking prescription medications to slim down, while others swear by intermittent fasting and other diet fads, but new research shows that they're all likely barking up the wrong trees.

There isn't a...